MARKET

DVAX

DVAX

Dynavax Technolo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.74
+0.78
+6.02%
Opening 15:05 07/05 EDT
OPEN
12.84
PREV CLOSE
12.96
HIGH
13.77
LOW
12.81
VOLUME
1.17M
TURNOVER
8.29M
52 WEEK HIGH
21.39
52 WEEK LOW
7.26
MARKET CAP
1.74B
P/E (TTM)
26.44
1D
5D
1M
3M
1Y
5Y
10 Small-Cap Stocks to Buy According to Ken Fisher
In this article, we discuss 10 small-cap stocks to buy according to Ken Fisher. If you want to skip our detailed analysis of Fisher Asset Management’s philosophy, hedge fund returns, and history, go directly to 5 Small-Cap Stocks to Buy According to Ken Fi...
Insider Monkey · 5d ago
What Kind Of Shareholders Hold The Majority In Dynavax Technologies Corporation's (NASDAQ:DVAX) Shares?
A look at the shareholders of Dynavax Technologies Corporation ( NASDAQ:DVAX ) can tell us which group is most...
Simply Wall St. · 06/28 11:51
Exact Sciences (EXAS) Surges 6.9%: Is This an Indication of Further Gains?
Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks · 06/27 13:13
Clover COVID vaccine's booster shot shows response against Omicron variants
Clover Biopharmaceuticals said that a third dose of its COVID-19 vaccine showed neutralizing antibody levels against Omicron variants in a trial. Clover noted that it created its COVID-19 vaccine candidate by
Seekingalpha · 06/27 11:00
Clover’s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster
SCB-2019 (CpG 1018/Alum) as a third dose exhibited a 19-fold boost in neutralizing antibodies against Omicron BA.2 variant among baseline seronegative participantsNew positive data adds to growing body of evidence supporting potential use of SCB-2019 (CpG ...
GlobeNewswire · 06/27 10:04
Myovant Sciences (MYOV) Moves 7.7% Higher: Will This Strength Last?
Myovant Sciences (MYOV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks · 06/20 11:36
Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines
-- Study to evaluate SCB-2019 (CpG 1018/Alum) as a heterologous booster in individuals previously vaccinated with CoronaVac™ (Sinovac Inactivated Vaccine), Comirnaty® (Pfizer mRNA Vaccine), and Vaxzevria® (AstraZeneca Viral Vector Vaccine) -- -- Safety & i...
GlobeNewswire · 06/14 00:12
Clover Provides Update on 2022 Corporate Milestones
-- Changxing manufacturing facility readiness and CMC activities impacted by COVID-19 outbreak in China - the facility is now expected to be ready for GMP inspections in Q3-2022 -- -- Regulatory submissions to the China NMPA, EMA, and the WHO for SCB-2019 ...
GlobeNewswire · 06/05 11:13
More
No Data
Learn about the latest financial forecast of DVAX. Analyze the recent business situations of Dynavax Technolo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average DVAX stock price target is 25.75 with a high estimate of 30.00 and a low estimate of 20.00.
High30.00
Average25.75
Low20.00
Current 13.73
EPS
Actual
Estimate
-0.030.180.380.59
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 276
Institutional Holdings: 116.33M
% Owned: 92.10%
Shares Outstanding: 126.31M
TypeInstitutionsShares
Increased
72
8.54M
New
24
979.25K
Decreased
63
3.47M
Sold Out
19
792.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.78%
Pharmaceuticals & Medical Research
-0.30%
Key Executives
Non-Executive Chairman/Independent Director
Scott Myers
President/Chief Operating Officer
David Novack
Chief Executive Officer/Director
Ryan Spencer
Chief Financial Officer/Senior Vice President
Kelly MacDonald
Senior Vice President
Robert Janssen
Independent Director
Francis Cano
Independent Director
Julie Eastland
Independent Director
Andrew Hack
Independent Director
Daniel Kisner
Independent Director
Brent MacGregor
Independent Director
Peter Paradiso
Independent Director
Peggy Phillips
Independent Director
Natale Ricciardi
Independent Director
Elaine Sun
No Data
No Data
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

Webull offers kinds of Dynavax Technologies Corporation stock information, including NASDAQ:DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.